Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors

BACKGROUND: Localized ablative immunotherapies hold great promise in stimulating antitumor immunity to treat metastatic and poorly immunogenic tumors. Tumor ablation is well known to release tumor antigens and danger-associated molecular patterns to stimulate T-cell immunity, but its immune stimulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoover, Ashley R, Kaabinejadian, Saghar, Krawic, Jason R, Sun, Xiao-Hong, Naqash, Abdul Rafeh, Yin, Qian, Yang, Xinbo, Christopher Garcia, K, Davis, Mark M, Hildebrand, William H, Chen, Wei R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577935/
https://www.ncbi.nlm.nih.gov/pubmed/36253002
http://dx.doi.org/10.1136/jitc-2022-004973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577935/
https://www.ncbi.nlm.nih.gov/pubmed/36253002
http://dx.doi.org/10.1136/jitc-2022-004973

Ejemplares similares